38 results about "Dimethyl isosorbide" patented technology

A spray foaming dosage form comprising betamethasone valerate, dimethyl isosorbide, propylene glycol, non ionic surfactant, sodium dodecyl sulphate, a buffer, optional preservative, optional further excipients, and water.

Diesel cycle fuel compositions are described containing at least one dianhydrohexitol compound according to the general formula 2 and/or its

derived hydrocarbyl ethers or nitric ethers compounds, where the R′ and R″ substituents are both H or one or both of R′ and R″ is alkyl, cycloalkyl or phenyl, or one or both are —NO₂. A preferred fuel composition is that containing dimethyl isosorbide (DMI) added or not of isosorbide dinitrate (ISDN) as ignition improver. The dianhydrohexitols compounds form compositions with at least one of the components selected among petroleum-derived diesel fuel, biodiesel, ethanol and water. The mixture of DMI and ISDN has excellent cetane number (IQT). Still, the oxygenated nature of the dianhydrohexitols and related compounds of the fuel compositions inhibits soot formation upon burning of the said Diesel cycle fuel compositions.

A transdermal formulation of dihydropyridine calcium antagonists and specifically nifedipine, nimodipine and nitrendipine. The calcium antagonists are dispersed in a mixed liquid. The mixed liquid comprises varying mole fractions of cis-oleic acid and dimethylisosorbide dispersed in a polypropylene glycol base.

The invention discloses a lipstick with a lip enhancement effect and a preparation method thereof, and belongs to the technical field of cosmetics. The lipstick comprises a thickener, a film forming agent, a coloring agent, a filling agent, an emollient, a preservative and a functional additive; the functional additive is composed of a functional additive I, a functional additive II and a functional additive III; the functional additive I is a mixture of jojoba seed oil and a pomegranate flower extract; the functional additive II is a mixture of caprylic/capric triglyceride, dimethyl isosorbide, a sesame seed extract and tocopherol; the functional additive III is a mixture of bisabolol and a ginger root extract; the lipstick contains 0.3 to 5 mass percent of the functional additive I, 1 to5 mass percent of the functional additive II and 0.1 to 0.5 percent of the functional additive III. In addition, the preparation process of the lipstick is simple, and the prepared lipstick has a good lip enhancement effect.

The present disclosure relates to cosmetic compositions including surprisingly high amounts of trifluoromethylphenyl valylglycine, which provides a variety of beneficial properties to skin. The cosmetic compositions include: (a) about 1 wt. % to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; (b) about 2 to about 30 wt. % of two or more solubilizing solvents selected from ethoxydiglycol, dimethyl isosorbide, triethyl citrate, isopropyl lauryl sarcosinate, and propylene glycol; and (c) optionally, water; wherein all weight percentages are based on the total weight of the cosmetic composition.

A filter material adapted for use as a filter element of a smoking article is provided, the filter material being in the form of a fibrous tow that includes a plurality of filaments of a degradable polyester and a plasticizer composition applied thereto, the plasticizer composition and the degradable polyester having a Relative Energy Difference calculated using Hansen Solubility Parameters of less than about 1.3. Exemplary degradable polyesters include polyglycolic acid, polylactic acid, polyhydroxyalkanoates, polycaprolactone, polybutylene succinate adipate and copolymers or blends thereof. Exemplary plasticizer compositions include one or more of dimethylisosorbide, propylene carbonate, methylbenzyl alcohol, glycerol carbonate acetate, glycerol carbonate ethyl ether, and mixtures thereof, optionally in combination with triacetin. Filter elements and smoking articles, such as cigarettes, that contain the filter material are also provided.

A spray foaming dosage form comprising clobetasol propionate, dimethyl isosorbide, propylene glycol, polysorbate, sodium dodecyl sulphate, buffer, optional preservative, optional further excipients, and water.

A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol, and dimethyl isosorbide. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators.

The invention discloses sweat-resistant leather and a preparation method thereof. The sweat-resistant leather comprises a leather base layer, a bonding layer, a sweat-resistant layer and a silica gelsurface layer which are connected in sequence, and the sweat-resistant layer is prepared from the following components: leather powder, a treating agent, acrylic resin, cotton powder or fiber powder,hydrated aluminum chloride, cyclohexasiloxane, dimethyl isosorbide, an adhesive and a solvent. The preparation method of the sweat-resistant leather comprises the following steps: adding the acrylic resin and the treating agent into the leather powder, performing uniform mixing under stirring, and allowing the mixed material to stand for a period of time to obtain a first intermediate product; adding the cotton powder or the fiber powder, the hydrated aluminum chloride, the cyclohexasiloxane, the dimethyl isosorbide, the adhesive and the solvent into the first intermediate product, performinguniform stirring, and performing drying for a period of time to obtain a second intermediate product; pressing the second intermediate product to obtain the sweat-resistant layer; bonding the sweat-resistant layer to one surface of the leather layer through an adhesive; and coating the surface of the sweat-resistant layer by silica gel, and performing drying to obtain the silica gel layer. The sweat-resistant leather provided by the invention can prevent stink caused by sweat.

A method for preparing a dialkyloxydianhyrohexitol (dimethylisosorbide) composition by etherification of dianhydrohexitol (isosorbide). The aim is to achieve a “clean” method that avoids the use of a methylation agent such as dimethyl sulfate or methyl chloride, which generates stoechiometric quantities of salts, or expensive dialkyl-carbonates, wherein only one of the two methyl groups participates in the preparation of mixed isosorbide ethers. The method involves using at least one O-alkylation agent and a catalyst including an acid or an acid salt, preferably a catalyst having Lewis or BrØnsted acid properties. A device for carrying out the method wherein the device includes a vaporization oven and a reaction oven is also described.

Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of microbial conditions, in particular acne. The solvent system assists in the effective dissolution of the usnic acid or usnate and in targeting its delivery to relevant sites on the skin.

The invention discloses a quick-drying water-based anti-rust agent which is characterized by being prepared from the following components in parts by weight: 3-5 parts of silicone-acrylic emulsion, 3-5 parts of vinyl acetate-acrylic emulsion, 1-2 parts of xanthan gum, 1-2 parts of dimethyl isosorbide, 1-2 parts of sulfonated caster oil, 0.3-0.5 part of succinic acid, 0.5-1 part of sodium dodecyl benzene sulfonate, 0.2-0.4 part of ethylene glycol monobutyl ether, 1-2 parts of petroleum sodium sulfonate, 3-5 parts of hydroxypropyl methyl cellulose, 1-2 parts of sodium silicate, 0.5-1 part of sodium polyacrylate, 4-6 parts of a modifying additive and 30-40 parts of water. The anti-rust agent can quickly form a hard and tough protection film on the metal surface, and is anti-fouling, anti-static, good in corrosion resistance and high temperature resistance and long in protection time.

Sterile, stable pharmaceutical formulations of poorly water-soluble drugs dissolved in dimethyl isosorbide, a water-miscible solvent, as well as methods for their preparation and administration.

The present invention discloses a bitterness aversion preparation. The bitterness aversion preparation comprises 85-90 parts of a carrier solvent, 3-4 parts of a bitter substance and 8-12 parts of anadditive. A preparation method of the bitterness aversion preparation comprises the following steps: (1) dissolving dimethyl isosorbide in ethyl acetate in proportion and conducting even stirring to obtain a solution A; (2) adding isopropanol to the solution A and conducting stirring and mixing to obtain a solution B; (3) adding the bitter substance into the solution B, conducting stirring until the bitter substance is completely dissolved, then adding an acrylic acid (acrylate) /methyl methacrylate copolymer, and conducting sealed stirring to obtain a solution C; and (4) adding a pomelo fruitextract while stirring to the solution C, and conducting even mixing to obtain the bitterness aversion preparation. An anti-bite pen is provided with a water absorbent cotton pen core and the bitterness aversion preparation is filled into the water absorbent cotton pen core. The bitterness aversion preparation, the preparation method thereof, and the anti-bite pen disclosed by the invention havethe following beneficial effects: 1, a bitterness effect is good; and 2, cross-contamination is not caused.

A method of treating nail diseases by topically applying to the nails a composition containing undecylenic acid and tolnaftate, a urea-based component, a monohydric alcohol such as isopropanol, a diol such as propylene glycol, dimethyl isosorbide, and a carboxylic acid, preferably lactic acid.

A controlled release parenteral formulation for treatment of pain and inflammation is provided. The formulation includes an effective amount of: one or more active drug moiety. The drug moiety is selected from a group comprising aceclofenac or diclofenac or a combination thereof; One or more solvent moiety selected from a group comprising one or more of ethyl acetate, triacetin, di methyl iso sorbide, DMA, DMSO, PEG, PVP, PVA, Span 80, DCM, Benzyl alcohol, acetone or a combination thereof. The formulation, upon administration, has a release profile including an immediate burst release and the burst release is followed by a slow release of at least 18 to 24 hrs. The immediate burst release and the slow release of the drug moiety remains within the therapeutic window of the drug moiety.